Rescinnamine

Summary

Rescinnamine (CHEMBL1668) is an approved small-molecule antihypertensive agent (ATC C02AA01); indicated across 1 condition including hypertensive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C02AA01
• Indications: 1 condition
• Chemistry: 634.7 Da · C35H42N2O9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1668
Name	Rescinnamine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	5280954
ChEBI	CHEBI:28572
ATC	C02AA01
Molecular formula	C35H42N2O9
Molecular weight	634.7
InChIKey	SZLZWPPUNLXJEA-QEGASFHISA-N

SMILES: CO[C@H]1[C@@H](C[C@@H]2CN3CCC4=C([C@H]3C[C@@H]2[C@@H]1C(=O)OC)NC5=C4C=CC(=C5)OC)OC(=O)/C=C/C6=CC(=C(C(=C6)OC)OC)OC

IUPAC name: methyl (1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate

Pharmacological roles (ChEBI): antihypertensive agent.

Also known as: Apoterin s, Cartric, Cinnaloid, Cinnasil, Moderil, NSC-15628, Rescinamina, Rescinnamine, Rescisan, Resealoid, Reserpinine, Scinnamina

Patent coverage: 1,301 distinct patent families (3,124 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,121 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Lethal(3)malignant brain tumor-like protein 1, Alpha-1A adrenergic receptor, Sodium-dependent dopamine transporter, Voltage-gated inwardly rectifying potassium channel KCNH2, Voltage-dependent L-type calcium channel subunit alpha-1C, Prostaglandin G/H synthase 1.

Bioactivity

ChEMBL activities: 3 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
KCNH2	6	AC50	988	nM	CHEMBL_ACT_25118256
ADRA1A	5.46	AC50	3500	nM	CHEMBL_ACT_25138090
P22002	5.29	AC50	5159	nM	CHEMBL_ACT_25119811

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hypertensive disorder	4	MONDO:0005044	EFO:0000537

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).